Exelixis, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EXEL research report →
Range $49 – $65
Price Chart
About the company
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer.
- CEO
- Michael Morrissey
- IPO
- 2000
- Employees
- 1,077
- HQ
- Alameda, CA, US
Get TickerSpark's AI analysis on EXEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $16.25B
- P/E
- 18.93
- Fwd P/E
- 17.41
- PEG
- 0.46
- P/S
- 6.57
- P/B
- 8.79
- EV/EBITDA
- 15.11
- Div Yield
- 0.00%
- Gross Margin
- 96.26%
- Op Margin
- 40.19%
- Net Margin
- 35.45%
- ROE
- 45.54%
- ROIC
- 39.65%
Latest fiscal year · YoY change
- Revenue
- $2.32B+7.0%
- Gross Profit
- $2.24B+6.9%
- Op Income
- $872.19M
- Net Income
- $782.57M+50.1%
- EPS
- $2.88+60.0%
- OCF Growth
- +26.3%
- FCF Growth
- +33.2%
- 52W High
- $73.69
- 52W Low
- $39.71
- 50D MA
- $63.03
- 200D MA
- $52.75
- Beta
- 0.42
- RSI (14)
- 43
- Avg Volume
- 2.44M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Exelixis posted a strong Q3 with CABO growth, robust cash generation, and continued momentum behind zanzalintinib as the company’s next potential franchise.· October 29, 2026
- Total Q3 2026 revenue was approximately $659 million, with GAAP EPS of $0.88 and non-GAAP EPS of $0.97.
- U.S. CABO franchise net product revenues rose about 11% year over year to $605 million; global CABO franchise net product revenues also rose about 11% to $818 million.
- Gross-to-net for the cabozantinib franchise was about 29% in Q3; management now expects full-year 2026 gross-to-net deductions of about 30%.
- Cash and marketable securities were approximately $1.4 billion, and the company repurchased about $250 million of stock in Q3.
- Management said zanzalintinib remains the top R&D priority, with CRC, NET, RCC and other programs advancing and STELLAR-304 top-line data expected in Q1 next year.
For Q3 2026, Exelixis reported total revenues of approximately $659 million. GAAP net income was approximately $218 million, or $0.88 per share basic and $0.85 diluted; non-GAAP net income was approximately $240 million, or $0.97 per share basic and $0.94 diluted. U.S. cabozantinib franchise net product revenues were $605 million, CABOMETYX net product revenues were $603 million, and royalties from partners were about $52 million. Gross-to-net for the cabozantinib franchise was approximately 29%, and management updated full-year 2026 gross-to-net deductions to about 30%. Total operating expenses were approximately $390 million, and cash and marketable securities ended the quarter at approximately $1.4 billion. For the full year, management said it was updating guidance to reflect changes in cost of goods sold and tax rate estimates, and noted tax rate expectations should be at the federal rate or thereabouts longer term.
Mike Morrissey framed the quarter as a strong execution period and emphasized that Exelixis is building beyond CABO toward a multi-franchise oncology company. He said zanzalintinib is positioned to drive the next phase of growth, with CRC first and then multiple pivotal-trial waves across GU, GI and other settings. His tone was confident and long-term focused, while also stressing disciplined expense control and share repurchases.
Chris Senner highlighted the core financial drivers: approximately $659 million of revenue, $390 million of operating expenses, $64.7 million of tax provision, and $1.4 billion of cash and marketable securities. He said Q3 gross-to-net was about 29%, below Q2 mainly because of lower 340B discounts, and that the full-year gross-to-net assumption is now about 30%. He also detailed capital returns, noting roughly $250 million of share repurchases in the quarter, retiring about 4.5 million shares at an average price of $55.77, with about $348 million remaining under the authorized repurchase plan.
Analysts focused on 340B effects, zanzalintinib FDA discussions, STELLAR-304 timing and dropout/event-rate dynamics, and the size of the CRC and RCC opportunities. Management repeatedly declined to speculate on ongoing FDA interactions and trial specifics, but said STELLAR-304 is now close to clinical cutoff and top-line results are expected in Q1 next year. On 340B, Morrissey said the issue has had very little impact so far and that the business appears to be stabilizing. On CRC, management argued the third-line-plus opportunity remains large, with about 23,000 U.S. patients and roughly a $1.5 billion market opportunity at contemporary pricing.
The call pointed to sustained CABO growth, with 11% U.S. franchise revenue growth and strength across RCC and NET, plus continued commercial momentum in the community setting. Management also sounded increasingly constructive on zanzalintinib, citing seven ongoing Wave 1 trials, active Wave 2 planning, and a broad development plan that could support multiple future labels.
Management acknowledged a few uncertainties: ongoing FDA review for zanzalintinib, the fact that clinical trial sales can be choppy, and the need to wait for data in STELLAR-304 and other studies. They also noted that the NET business can be temporally uneven, which affected the decision to keep revenue guidance conservative despite strong quarter-over-quarter performance. Longer term, the size and timing of the zanza opportunity still depend on trial readouts, approvals, and how competitive CRC and RCC markets evolve.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.5%
- Shares Outstanding
- 251.36M
- Float Shares
- 209.76M
of shares held by institutions
781 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for EXEL, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 29.74M | ▲ 668.07K |
| Vanguard Group Inc | 25.49M | ▼ 574.12K |
| Farallon Capital Management, L.L.C. | 13.47M | ▲ 357.00K |
| Renaissance Technologies LLC | 12.79M | ▼ 635.30K |
| Vanguard Portfolio Management LLC | 11.96M | ▼ 87.36K |
| Aqr Capital Management LLC | 11.02M | ▼ 2.07M |
| Vanguard Capital Management LLC | 10.76M | ▼ 192.42K |
| State Street Corp | 10.52M | ▲ 551.42K |
| Fuller & Thaler Asset Management, Inc. | 8.80M | ▼ 133.46K |
| Geode Capital Management, LLC | 8.24M | ▲ 592.23K |
| Lsv Asset Management | 7.89M | ▼ 256.75K |
| Morgan Stanley | 6.31M | ▲ 1.79M |
Held by 820 ETFs
Biggest fund positions in EXEL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 10, 26 | Beckerle Mary C | sell | 9,812 |
| Jun 1, 26 | WYSZOMIERSKI JACK L | sell | 3,925 |
| Jun 1, 26 | Eckhardt Sue Gail | sell | 9,812 |
| May 27, 26 | PAPADOPOULOS STELIOS | other | 8,367 |
| May 27, 26 | Heyman Tomas J. | other | 8,367 |
| May 27, 26 | Eckhardt Sue Gail | other | 8,367 |
| May 27, 26 | Smith Julie | other | 8,367 |
| May 27, 26 | Freire Maria C | other | 8,367 |
| May 27, 26 | Beckerle Mary C | other | 8,367 |
| May 27, 26 | Oliver Bob | other | 8,367 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EXEL coverage
Recent articles, reports, and earnings notes.
No research on EXEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EXEL report →Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?
zacks.com · Nov 20
74,363 Shares of Exelixis, Inc. $EXEL Purchased by Edgestream Partners L.P.
defenseworld.net · Nov 20
Exelixis Eyes Q1 Zanza Data as It Plans Beyond CABO
marketbeat.com · Nov 18
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything
fool.com · Nov 16
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.
fool.com · Nov 13
Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib
marketbeat.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.